Khalil Kaid
Cardiovascular Disease · Maplewood, NJNPI 1285651109
Payments from drug & device makers
Across 355 payments — averaging $59.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$6K
- Abbott$3K
- Medtronic$2K
- Shockwave Medical, Inc$2K
- Penumbra, Inc.$1K
- Bard Peripheral Vascular, Inc.$1K
- plus $6K from 36 others
What the payments were for
- Speaking & faculty fees$1251%
- Travel & lodging$3,86218%
- Food & beverage$17,16781%
- Education$1281%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 96 | $5,760 |
| Abbott | 30 | $2,609 |
| Medtronic(2 entities) | 19 | $2,404 |
| Shockwave Medical, Inc | 24 | $1,981 |
| Penumbra, Inc. | 5 | $1,262 |
| Bard Peripheral Vascular, Inc. | 17 | $1,028 |
| Cardiovascular Systems Inc. | 13 | $696 |
| Novartis | 37 | $612 |
| Cardiva Medical, Inc. | 14 | $539 |
| Abiomed | 4 | $453 |
| Philips North America LLC | 8 | $387 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 7 | $351 |
| Heartflow, Inc. | 12 | $342 |
| Edwards Lifesciences | 4 | $258 |
| Cagent Vascular Inc | 2 | $216 |
| ZOLL Circulation Inc | 2 | $213 |
| Siemens Medical Solutions USA, Inc. | 2 | $209 |
| Cardinal Health 200 LLC | 2 | $171 |
| Cvrx, Inc. | 1 | $147 |
| Endologix LLC | 2 | $147 |
| Saranas, Inc. | 1 | $147 |
| Organogenesis Inc. | 1 | $125 |
| Stryker | 1 | $125 |
| Irhythm Technologies, Inc. | 3 | $115 |
| Pfizer | 7 | $108 |
| Johnson & Johnson | 7 | $104 |
| Inari Medical, Inc. | 3 | $104 |
| Cordis US CORP. | 1 | $97 |
| AstraZeneca | 5 | $73 |
| Imperative Care, Inc | 2 | $65 |
| Boehringer Ingelheim | 4 | $57 |
| Merck | 3 | $52 |
| Digirad Health, Inc | 1 | $51 |
| Novo Nordisk | 3 | $46 |
| E.r. Squibb & Sons, L.L.C. | 3 | $43 |
| Procyrion, Inc. | 1 | $39 |
| Lilly USA, LLC | 2 | $30 |
| Amgen | 2 | $30 |
| Atricure, Inc. | 1 | $29 |
| Terumo Medical Corporation | 1 | $23 |
| Preventice Services, LLC | 1 | $17 |
| Alnylam Pharmaceuticals Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL - THERAPIES$2,047
- Indigo System$1,262
- ClosureFast$1,171
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$778
- MitraClip$763
- LUTONIX$621
- Xience V coronary stent system$511
- Impella$420
- SYMPLICITY G3$320
- SHOCKWAVE INTRAVASCULAR LITHOTRIPSY (IVL) SYSTEM WITH THE SHOCKWAVE C2+ CORONARY$270
- ONYX FRONTIER$267
- WATCHMAN Access System$240
- Watchman$220
- Serrantor$216
- Diamondback Peripheral$190
- Diamondback Coronary$190
- AMPLATZER$188
- Barostim Neo System$147
- COREVALVE EVOLUT R$143
- AMPLATZER AMULET$142
How this compares
$21,282 in reported general payments places this provider in the 85th percentile of 1,006 cardiovascular disease providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 103 | $131,996 |
| EntrestoSacubitril/Valsartan | 56 | $81,888 |
| XareltoRivaroxaban | 12 | $15,125 |
| BrilintaTicagrelor | 11 | $12,026 |
| FarxigaDapagliflozin Propanediol | 14 | $10,773 |
| Metoprolol Succinate | 180 | $2,618 |
| Atorvastatin Calcium | 197 | $2,347 |
| Nebivolol Hcl | 24 | $2,188 |
| ClopidogrelClopidogrel Bisulfate | 169 | $2,134 |
| Rosuvastatin Calcium | 72 | $1,667 |
| Hydralazine Hcl | 36 | $1,105 |
| Amlodipine Besylate | 188 | $1,063 |
| Losartan Potassium | 65 | $1,000 |
| Cilostazol | 32 | $933 |
| Olmesartan Medoxomil | 44 | $907 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $108 | $131,996103 claims |
| NovartisEntresto | $612 | $81,88856 claims |
| AstraZenecaBrilinta, Farxiga | $73 | $22,79825 claims |
| Johnson & JohnsonXarelto | $104 | $15,12512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,006 cardiovascular disease providers in New Jersey.
Other cardiovascular disease in Maplewood
- Robert KippermanMorristown$5.3M
- Sharan MahalBridgewater$3.5M
- Linda GillamMorristown$2.2M
- Mark GelerntHaddon Heights$2M
- Robert FishbergSpringfield$1.9M
- Dilip ViswanathHaddon Heights$1.8M
- Marc CohenNewark$1M
- Jasjit WaliaElizabeth$859K
- Sajjad SabirCamden$742K
- John CovaleskyManalapan$716K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.